## NBIX: Neurocrine Biosciences, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.27 indicates fundamental undervaluation. Caution: momentum weakening (-7.3% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($135.42)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 8
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. HC Wainwright & Co. Maintains Neurocrine Biosciences (NBIX) Buy Recommendation**
- Source: Nasdaq | 20251218T080930 | Somewhat-Bullish | Relevance: 100%
- HC Wainwright & Co. has reiterated its Buy recommendation for Neurocrine Biosciences (NBIX), with an average one-year price target of $177.73/share, suggesting a 25.43% upside from its current price. The article highlights institutional ownership changes, fund sentiment, and key shareholder positions, noting a bearish put/call ratio despite the positive analyst outlook.

**2. Neurocrine Biosciences (NASDAQ:NBIX) Director Leslie Norwalk Sells 5,000 Shares**
- Source: MarketBeat | 20251217T230851 | Somewhat-Bullish | Relevance: 100%
- Neurocrine Biosciences (NASDAQ:NBIX) Director Leslie Norwalk sold 5,000 shares of the company's stock for $761,150.00, reducing her stake by over 40%. This transaction follows strong Q3 results where the company exceeded EPS and revenue expectations. Analysts largely maintain positive ratings and price targets for NBIX.

**3. Neurocrine Biosciences (NASDAQ:NBIX) Director Leslie Norwalk Sells 1,190 Shares**
- Source: MarketBeat | 20251217T230851 | Neutral | Relevance: 100%
- Neurocrine Biosciences (NASDAQ:NBIX) Director Leslie Norwalk sold 1,190 shares of the company's stock for $184,557.10 on December 16, 2025, reducing her stake by 16.02%. The sale follows a strong Q3 earnings report where the company beat analyst expectations for both EPS and revenue, though the stock traded down on Wednesday. Analysts maintain a "Moderate Buy" rating with an average target price of $174.76 for NBIX.

**4. Key facts: HC Wainwright maintains 'Buy' on Neurocrine; price target rises**
- Source: TradingView â€” Track All Markets | 20251217T200851 | Bullish | Relevance: 100%
- HC Wainwright & Co. has reiterated its 'Buy' rating for Neurocrine Biosciences, Inc. (NBIX) and increased the stock's price target from $168.00 to $198.00. Neurocrine Biosciences is advancing a diverse pipeline in neurology, psychiatry, and endocrinology, with two late-stage assets currently in Phase 3 trials.

**5. Neurocrine Bio. stock rating reiterated at Outperform by RBC Capital**
- Source: Investing.com Nigeria | 20251217T190851 | Bullish | Relevance: 100%
- RBC Capital has reaffirmed its Outperform rating for Neurocrine Biosciences (NASDAQ:NBIX) with a $180 price target, citing the company's strong revenue growth, R&D progress, and robust cash position. Despite limited new information on later-stage assets, the firm projects Ingrezza sales to exceed consensus estimates and expects further stock appreciation. This positive outlook is supported by recent price target increases from Mizuho and TD Cowen, driven by the strong performance of Crenessity and favorable Medicare conditions for Ingrezza.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 5, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-17 | HC Wainwright & | $198 | $168 | +18% |
| 2025-12-12 | Mizuho | $175 | $146 | +20% |
| 2025-12-11 | Stifel | $188 | $183 | +3% |
| 2025-12-08 | RBC Capital | $180 | $160 | +12% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-17 | HC Wainwright & | main | Buy |
| 2025-12-12 | Mizuho | main | Neutral |
| 2025-12-11 | Stifel | main | Buy |
| 2025-12-08 | RBC Capital | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 10 ($2.96M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 53.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Blackrock Inc.: 12.7% (-1.9%)
- Vanguard Group Inc: 9.7% (-1.0%)
- JPMORGAN CHASE & CO: 9.5% (+122.0%)
- Dodge & Cox Inc.: 5.6% (-0.2%)
- State Street Corpora: 4.4% (-2.7%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-7.3% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 5 raises (avg +13%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 0.27 indicates undervaluation relative to growth. Forward P/E 15.7x attractive for 33% earnings growth. Quality metrics strong (margin 16%). Balance sheet: strong liquidity (3.4x), low leverage (D/E 0.42). Analyst sentiment positive (5 raises, avg +13%). Insider selling cluster ($3.0M in 90 days), potential headwind. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $14.5B |
| Beta | 0.27 |
| 52W Range | $84.23 - $160.18 |
| Short Interest | 5.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.27 |
| Forward P/E | 15.7 |
| Current P/E | 21.0 |
| YoY Growth | 33.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 3.6% to -3.6% (-7.3% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.6pp (needs >4.0% for momentum thesis). AM_20 at -3.3% indicates price below own 20MA trend. Underperforming sector by 3.5pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.12x) but short-term weakness (below SMA20). MACD histogram bearish (-1.45), momentum weakening. RSI neutral at 44. Elevated volume (1.8x 20MA), institutional activity likely. OFD pattern: +SLH (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -3.61% (CS: 17) | Weak |
| RSI_14 | 44.3 | Neutral |
| MACD Histogram | -1.45 | Bearish |
| vs SMA20 | 0.967x | Below |
| vs SMA50 | 0.994x | Below |
| vs SMA200 | 1.118x | Above |

### Decision

- **Verdict:** HOLD
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $145.00
- **Stop Loss:** $135.42 (6.6% risk)
- **Target:** $164.16 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 125
- **Position Value:** $18,125.00
- **Portfolio %:** 18.12%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-02-05 (Est: $2.41)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.07 | $2.17 | +4.9% |
| 2025Q2 | $1.50 | $1.65 | +9.6% |
| 2025Q1 | $1.09 | $0.70 | -36.0% |
| 2024Q4 | $1.93 | $1.69 | -12.4% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*